Writing China’s Own Guidelines: Professor Zefei Jiang on the Evolution and Global Vision of the CSCO Breast Cancer Guidelines

Writing China’s Own Guidelines: Professor Zefei Jiang on the Evolution and Global Vision of the CSCO Breast Cancer Guidelines

As one of the five initial professional guideline projects launched by the Chinese Society of Clinical Oncology (CSCO) in 2016, the CSCO Breast Cancer Guidelines (CSCO BC Guidelines) have become a cornerstone of breast cancer care in China. Since the publication of the first edition in 2017, the guidelines have undergone yearly updates, evolving in both content and format. Today, they are available in multiple versions—including Chinese and English editions, pocket guides, patient education materials, and AI-based platforms—earning broad recognition from Chinese clinicians and international oncology peers alike.
Professor Zhengqiang Yang Offers In-Depth Interpretation of the 2024 Edition of the Primary Liver Cancer Guidelines: Updates in Interventional and Local Therapies

Professor Zhengqiang Yang Offers In-Depth Interpretation of the 2024 Edition of the Primary Liver Cancer Guidelines: Updates in Interventional and Local Therapies

Since the release of the 2022 edition of the Primary Liver Cancer Diagnosis and Treatment Guidelines, numerous high-quality studies—both domestic and international—have advanced the field of hepatocellular carcinoma (HCC), especially in diagnosis, staging, and treatment. Research reflecting China's real-world clinical settings has provided important theoretical guidance for the management of liver cancer. Building on accumulated clinical experience, the National Health Commission has organized expert teams to revise the guidelines, culminating in the publication of the 2024 edition, which introduces comprehensive updates across screening, diagnosis, and treatment.
Cancer Patients Rehabilitation Rally is Underway!

Cancer Patients Rehabilitation Rally is Underway!

On April 20, 2025, the "Beyond Limits" Cancer Patients Rehabilitation Rally was officially launched across China. Organized by the Cancer Rehabilitation Society of CACA , and supported by Hengrui Pharmaceuticals, the initiative harnesses digitization and other cutting-edge technologies to enhance long-term survival rates and quality of life for cancer patients.